Shenzhen Celconta Life Science Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Shenzhen Celconta Life Science Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC (NCT07043907) | Shenzhen Celconta Life Science Co., Ltd. | 2025-07-08 |
| Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T) (NCT06782425) | Shenzhen Celconta Life Science Co., Ltd. | 2025-01-01 |
| Treating Nectin-4-positive Advanced Breast Cancer with XKDCT293 (Nectin-4-CAR-T) (NCT06724835) | Shenzhen Celconta Life Science Co., Ltd. | 2024-03-11 |
| PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors (NCT06897228) | Shenzhen Celconta Life Science Co., Ltd. | 2024-02-18 |
Track Shenzhen Celconta Life Science Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.